Generate a tailored SOP for Dr. Mark Lemmon. Improve your application with a focused, well-structured draft.
Mark Lemmon is the Alfred Gilman Professor of Pharmacology and Co-Director of the Yale Cancer Biology Institute. He returned to Yale in 2015 after spending 19 years on the faculty of the University of Pennsylvania’s Perelman School of Medicine, where he held the position of George W. Raiziss Professor of Biochemistry and Biophysics and Chair of the Biochemistry Department. In 2016, he was elected a Fellow of the Royal Society, the UK's national academy of sciences. Dr. Lemmon has received numerous awards, including the Dorothy Crowfoot Hodgkin Award from the Protein Society and the Stanley N. Cohen Biomedical Research Award from the University of Pennsylvania. His research focuses on understanding signaling networks controlled by receptor tyrosine kinases (RTKs), which are often mutated and involved in the development of various cancers. The Lemmon lab employs biochemical, structural, and cellular approaches to study RTK functions and collaborates with clinical groups to enhance therapeutic strategies. His work has advanced our understanding of RTK signaling, which is crucial for developing targeted therapies.
Yale School of Medicine • New Haven, CT, United States
Alfred Gilman Professor of Pharmacology and Co-Director of the Cancer Biology Institute.
University of Pennsylvania • Philadelphia, PA, United States
Held the position of Chair of the Biochemistry department and Investigator at the Abramson Family Cancer Research Institute.
Administered via the Graduate School of Arts and Sciences (GSAS). GRE General is optional for PhD.